Stockreport

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer [Yahoo! Finance]

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe Relacorilant plus nab-paclitaxel has [Read more]